Microbot Medical Inc. (MBOT) is a Hingham, Massachusetts-based medical device company commercializing LIBERTY, an FDA-cleared, single-use robotic system for peripheral endovascular procedures. In Monday's session the stock fell 38.78%, trading at $0.60 against a prior close of $0.9787, extending a decline that has now erased more than two-thirds of its value since August. The move was confirmed as a sharp downward repricing, not a rebound. The immediate reason cited by the market: a steep sequential collapse in quarterly revenue, a negative gross margin, and commentary pointing to a slower-than-expected hospital adoption curve.
The company's Form 10-Q for the quarter ended September 30, filed after Friday's close, showed revenue of just $72,000 — a roughly 70% decline from the $241,000 booked in the second quarter. Management attributed the drop to the timing of customer reorders, third-quarter seasonality, and the four-to-six-month hospital Value Analysis Committee process, which has left multiple prospective accounts still awaiting approval rather than placing orders.
Cost of revenue reached $1.095 million, including an $815,000 inventory write-down, producing a negative gross margin. The net loss widened to $5.84 million from $3.58 million a year earlier, and the per-share loss of $0.09 came in slightly worse than the $0.08 consensus. Because LIBERTY is effectively the company's only revenue stream, the sequential deceleration struck directly at the central pillar of the investment case: that a consumable-driven, single-use robot would generate a fast-ramping installed base.
The company did highlight offsetting operational progress — procedure utilization rose 44% quarter over quarter, customer accounts grew to 12 from 10, sales territories expanded to ten, and 100% of customers who exhausted initial inventory reordered. Management also said cost reductions and a planned second production line could deliver a positive gross margin during 2027. Investors, focused on near-term revenue visibility, did not treat those points as sufficient.
The 10-Q and the accompanying release landed late Friday and over the weekend, so the full repricing came Monday. The stock had already slipped 4.98% on Friday as the filing circulated, then gapped lower at the open as the detailed disclosure of revenue mix, inventory valuation, and burn rate reached a wider audience. This pattern — a modest Friday drift followed by a much larger Monday gap — is consistent with a fundamentally driven reassessment rather than a single intraday headline.
Following the results, sell-side price targets were trimmed, with the average target reduced by roughly 16% to about $5.74 on adoption concerns. Even after those cuts, published targets sit many multiples above the current share price, a gap that reflects long-dated assumptions about LIBERTY's rollout rather than near-term earnings power.
The stock is also now trading far below $1, a level that historically complicates institutional ownership and raises the possibility of minimum-bid-price compliance questions under Nasdaq listing rules if the weakness persists.
The decline was concentrated in these shares rather than reflecting a broad risk-off session; no macro data release or sector event of comparable scale coincided with the move. Turnover in recent weeks has averaged roughly half a million to 700,000 shares a day, and Monday's tape was active from the opening bell, with the stock trading in a narrow band near $0.60 after the initial gap.
Technically, the shares broke below the $0.94–$0.95 support zone that had contained the October lows and are now more than 65% below their August level near $1.89. Both the 50-day and 200-day moving averages sit far above the current price, leaving the stock in a persistent downtrend with no nearby technical floor.
The score runs from 0, meaning no meaningful news and a move normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Here it is 77 out of 100.
The verified news was substantial: a 70% sequential revenue decline, a negative gross margin driven partly by an inventory write-down, and a widening loss at a company whose valuation rests entirely on commercial adoption. Against a market capitalization that has shrunk to roughly $40 million, that is material. The price action was equally unusual. The stock's typical daily move over the past 60 sessions is about 2.5%, so Monday's decline was roughly 15 times normal, and no session in that stretch came close to matching it — the largest was around 9.4%. Strong news and a rare move combine into a high score.
Attention now shifts to fourth-quarter order activity, the pace at which accounts exit the Value Analysis Committee pipeline, and initial orders under the new Israeli distribution agreement. Management has guided toward 12 sales territories by year-end and a European CE mark by the end of the first quarter of 2027, both of which carry execution risk. The next quarterly report will be scrutinized for evidence that revenue has re-accelerated after the seasonal dip. With $62 million in cash and securities and a quarterly burn in the single-digit millions, the balance sheet funds operations for more than a year, but the gap between cash on hand and market value invites questions about how the company funds growth beyond that window — and whether another equity raise becomes necessary. The 9.4% short interest adds volatility risk in both directions.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions from a library of hundreds of AI trading bots covering thousands of tickers. Bots differ widely by strategy logic, holding period, risk profile, traded symbols, and performance metrics, so the featured lineup rotates as conditions change. It is a practical starting point for traders who want to compare live bot performance rather than screen charts manually. Review the current Trending AI Robots selection to see which strategies are working now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The Aroon Indicator for MBOT entered a downward trend on November 02, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 248 similar instances where the Aroon Indicator formed such a pattern. In 222 of the 248 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBOT as a result. In 70 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for MBOT turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 40 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBOT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBOT advanced for three days, in 150 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
MBOT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. MBOT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.082) is normal, around the industry mean (4.142). P/E Ratio (-4.440) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (263.158) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBOT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which specializes in the research, design, development and commercialization of micro-robotics assisted medical technologies
Industry MedicalNursingServices